{
  "abstract": "Background and Importance Oritavancin is a lipoglycopeptide active against multidrug-resistant gram-positive cocci. Its prolonged half-life (245 h) enables single-dose administration, potentially reducing hospital stay and costs.Aim and Objectives To describe real-world use of oritavancin regarding indications, dosage, effectiveness and safety in clinical practice, and to assess its economic impact when administered at hospital discharge.Material and Methods A retrospective observational study was conducted including all patients treated with oritavancin from September 2023 (date of inclusion in the hospital formulary) to July 2025 in a tertiary hospital. Variables evaluated: age, sex, type of infection, isolated microorganism, treatment indication, dosage, clinical cure (absence of clinical signs of infection), results of microbiological cultures, 30-day mortality, adverse events, hospital stay and economic cost.Results Twenty-eight infection cases in 25 patients were analysed. Most were male (80%, n=20) with a median age of 54 (43–67) years. Main indications were skin and soft tissue infections (SSTIs) (64.30%, n=18) and osteoarticular infections (OAI) (28.60%, n=8). Targeted therapy based on antibiogram was used in 46.4% (n=13) of cases. The most frequent pathogens were Enterococcus faecalis (14.29%, n=4), Enterococcus faecium (14.29%, n=4), Staphylococcus epidermidis (14.29%, n=4), Methicillin-resistant Staphylococcus aureus (14.29%, n=4) and Methicillin-susceptible Staphylococcus aureus (10.71%, n=3). 85.71% (n=24) of the cases received a single 1200 mg dose, while 14.30% (n=4) received a second 800 mg dose 8-12 days later. 46.43% (n=13) received treatment immediately before discharge.Regarding effectiveness, 71.43% (n=20) achieved complete clinical cure, 14.29% (n=4) relapsed, and no 30-day mortality was observed. Post-cure cultures were performed in 21.4% (n=6), all negative. Regarding safety, only one patient developed adverse events in two cases. One case involved general malaise post-infusion, and another a severe infusion-related reaction.The treatment cost per patient ranged €1,342–€2,237, whereas avoided hospitalisation costs ranged €4,550–€27,300 from one to six weeks, depending on the diagnosis. Estimated savings for patients receiving oritavancin at discharge ranged €30,074–€337,459.Conclusion and Relevance Oritavancin demonstrated an adequate effectiveness and safety profile with high clinical cure rates and few adverse events, although vigilance is warranted due to potential infusion-related reactions. Beyond its approved indication in SSTIs, it proved effective in OAI. Its administration at discharge enabled substantial cost savings by avoiding prolonged inpatient care. Further studies are needed to confirm its role in antibiotic stewardship and resource optimisation.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospital Universitari I Politècnic La Fe, Hospital Pharmacy Service, Valencia, Spain"
      ],
      "name": "S Roldán Martínez"
    },
    {
      "affiliations": [
        "Hospital Universitari I Politècnic La Fe, Hospital Pharmacy Service, Valencia, Spain"
      ],
      "name": "M Correa Ballester"
    },
    {
      "affiliations": [
        "Hospital Universitari I Politècnic La Fe, Hospital Pharmacy Service, Valencia, Spain"
      ],
      "name": "E Monte Boquet"
    },
    {
      "affiliations": [
        "Hospital Universitari I Politècnic La Fe, Hospital Pharmacy Service, Valencia, Spain"
      ],
      "name": "D Gallen Soria"
    },
    {
      "affiliations": [
        "Hospital Universitari I Politècnic La Fe, Hospital Pharmacy Service, Valencia, Spain"
      ],
      "name": "JM Campos Barrachina"
    },
    {
      "affiliations": [
        "Hospital Universitari I Politècnic La Fe, Hospital Pharmacy Service, Valencia, Spain"
      ],
      "name": "B Arnau Blasco"
    },
    {
      "affiliations": [
        "Hospital Universitari I Politècnic La Fe, Hospital Pharmacy Service, Valencia, Spain"
      ],
      "name": "M Chovi Trull"
    },
    {
      "affiliations": [
        "Hospital Universitari I Politècnic La Fe, Hospital Pharmacy Service, Valencia, Spain"
      ],
      "name": "L Escobar Hernández"
    },
    {
      "affiliations": [
        "Hospital Universitari I Politècnic La Fe, Hospital Pharmacy Service, Valencia, Spain"
      ],
      "name": "M Rodenas Rovira"
    },
    {
      "affiliations": [
        "Hospital Universitari I Politècnic La Fe, Hospital Pharmacy Service, Valencia, Spain"
      ],
      "name": "J García Pellicer"
    },
    {
      "affiliations": [
        "Hospital Universitari I Politècnic La Fe, Hospital Pharmacy Service, Valencia, Spain"
      ],
      "name": "JL Poveda Andrés"
    }
  ],
  "title": "4CPS-021 Clinical outcomes and economic evaluation of oritavancin therapy: a real-world study",
  "uid": "146f988d-76b9-56da-9e6e-1dfa5422edbc"
}